Poseida’s Solid Tumor CAR-T Shows Early Promise, But Safety Will Be Closely Watched
Promising Signs In Prostate Cancer
Developing CAR-Ts against solid tumors that are both safe and effective is proving a huge technical challenge, but San Diego biotech Poseida believes it has made important progress.
You may also be interested in...
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.